Alembic Pharma USFDA Approval Boosts Portfolio; Shares Rise 1.63%

Mumbai, April 16: Alembic Pharmaceuticals Limited has received final approval from the US Food and Drug Administration for its Methotrexate Injection, adding another product to its steadily expanding US generics portfolio.

The approval covers both multi-dose and single-dose formats. Specifically, 50 mg/2 mL multi-dose vials and 1 g/40 mL single-dose vials. These fall under the abbreviated pathway, meaning they are therapeutically equivalent to an already approved reference drug.

Methotrexate is not a niche therapy. It sits across multiple treatment areas, from oncology indications such as leukaemia and lymphoma to chronic autoimmune conditions like rheumatoid arthritis and psoriasis. It tends to support consistent demand, even if pricing dynamics in the US generics space remain competitive.

The company noted that this takes its cumulative USFDA approvals to 236, including 218 final clearances.

Stock Market Snapshot

Alembic Pharmaceuticals share price moved up following the announcement, though the reaction remained contained rather than sharp.

As of 11:27 IST on April 16, 2026, the stock was trading at ₹746.80, up ₹12.00 or 1.63% from the previous close of ₹734.80, according to exchange data. During the session, it traded between ₹733.25 and ₹753.65.

The move suggests that while the approval is directionally positive, the market may be viewing it as incremental. Approvals in isolation rarely drive sharp re-rating unless backed by meaningful revenue contribution or limited competition.

Strategy Focused On Complex And Regulated Markets

Alembic Pharmaceuticals has been gradually sharpening its focus on regulated markets, particularly the United States. Within that, injectables and niche formulations have become an area of interest.

These segments tend to offer relatively better entry barriers compared to plain-vanilla generics. They also require more specialised manufacturing capabilities and regulatory compliance, which can support more stable positioning over time.

The company continues to build its pipeline through ANDA filings and approvals, aiming for a steady flow of launches rather than dependence on a few large products.

Incremental Gains, Long-Term Build-Out

This approval adds to a growing base of products that collectively shape revenue visibility in the US business.

For investors, the focus is likely to remain on execution. Timely commercialisation, pricing discipline and sustaining approvals pipeline will determine how effectively these regulatory wins translate into financial performance.

Source:

• https://www.nseindia.com/get-quote/equity/APLLTD/Alembic-Pharmaceuticals-Limited
• https://nsearchives.nseindia.com/corporate/APLLTD_16042026111652_Intimation_to_SE_Press_Release_FA.pdf